Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange

E. Bobbio-Pallavicini, C. Porta, R. Centurioni, L. Gugliotta, N. Vianelli, F. Tacconi, A. Billio, E. Ascari, O. Prinoth, M. Rubertelli, G. Ongaro, F. Rodeghiero, C. Perotti, G. Busnach, G. Cambie, A. Canevari, M. Carotenuto, G. Leda, G. Bertrand

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Among all the patients treated by the Italian Cooperative Group for TTP, we retrospectively reviewed the results obtained using vincristine (VCR) in 8 TTP patients (4 men and 4 women, average age: 39.25 years, range: 23-48) who did not respond to combined apheretic and pharmacologic treatment. All patients, after failing to respond to treatment, were started on VCR at the dose of 2 mg, i.v., once a week. Despite this treatment, 4 patients (50%) died 1, 7, 12 and 25 days after the first VCR dose, respectively. The other 4 patients who received VCR achieved complete remission 24, 30, 40 and 50 days from the beginning of the treatment. Total doses of VCR ranged from 2 to 6 mg in the deceased group, and from 6 to 14 mg in the cured patients. In our experience, VCR is a promising agent to treat TPP patients resistant to conventional plasma-exchange and pharmacologic therapy.

Original languageEnglish
Pages (from-to)222-226
Number of pages5
JournalEuropean Journal of Haematology
Volume52
Issue number4
Publication statusPublished - 1994

Fingerprint

Thrombotic Thrombocytopenic Purpura
Plasma Exchange
Vincristine
Therapeutics

Keywords

  • plasma-exchange
  • refractory disease
  • TTP
  • vincristine

ASJC Scopus subject areas

  • Hematology

Cite this

Bobbio-Pallavicini, E., Porta, C., Centurioni, R., Gugliotta, L., Vianelli, N., Tacconi, F., ... Bertrand, G. (1994). Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. European Journal of Haematology, 52(4), 222-226.

Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. / Bobbio-Pallavicini, E.; Porta, C.; Centurioni, R.; Gugliotta, L.; Vianelli, N.; Tacconi, F.; Billio, A.; Ascari, E.; Prinoth, O.; Rubertelli, M.; Ongaro, G.; Rodeghiero, F.; Perotti, C.; Busnach, G.; Cambie, G.; Canevari, A.; Carotenuto, M.; Leda, G.; Bertrand, G.

In: European Journal of Haematology, Vol. 52, No. 4, 1994, p. 222-226.

Research output: Contribution to journalArticle

Bobbio-Pallavicini, E, Porta, C, Centurioni, R, Gugliotta, L, Vianelli, N, Tacconi, F, Billio, A, Ascari, E, Prinoth, O, Rubertelli, M, Ongaro, G, Rodeghiero, F, Perotti, C, Busnach, G, Cambie, G, Canevari, A, Carotenuto, M, Leda, G & Bertrand, G 1994, 'Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange', European Journal of Haematology, vol. 52, no. 4, pp. 222-226.
Bobbio-Pallavicini E, Porta C, Centurioni R, Gugliotta L, Vianelli N, Tacconi F et al. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. European Journal of Haematology. 1994;52(4):222-226.
Bobbio-Pallavicini, E. ; Porta, C. ; Centurioni, R. ; Gugliotta, L. ; Vianelli, N. ; Tacconi, F. ; Billio, A. ; Ascari, E. ; Prinoth, O. ; Rubertelli, M. ; Ongaro, G. ; Rodeghiero, F. ; Perotti, C. ; Busnach, G. ; Cambie, G. ; Canevari, A. ; Carotenuto, M. ; Leda, G. ; Bertrand, G. / Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. In: European Journal of Haematology. 1994 ; Vol. 52, No. 4. pp. 222-226.
@article{6b0b749d3a7747d28449363fcec56d60,
title = "Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange",
abstract = "Among all the patients treated by the Italian Cooperative Group for TTP, we retrospectively reviewed the results obtained using vincristine (VCR) in 8 TTP patients (4 men and 4 women, average age: 39.25 years, range: 23-48) who did not respond to combined apheretic and pharmacologic treatment. All patients, after failing to respond to treatment, were started on VCR at the dose of 2 mg, i.v., once a week. Despite this treatment, 4 patients (50{\%}) died 1, 7, 12 and 25 days after the first VCR dose, respectively. The other 4 patients who received VCR achieved complete remission 24, 30, 40 and 50 days from the beginning of the treatment. Total doses of VCR ranged from 2 to 6 mg in the deceased group, and from 6 to 14 mg in the cured patients. In our experience, VCR is a promising agent to treat TPP patients resistant to conventional plasma-exchange and pharmacologic therapy.",
keywords = "plasma-exchange, refractory disease, TTP, vincristine",
author = "E. Bobbio-Pallavicini and C. Porta and R. Centurioni and L. Gugliotta and N. Vianelli and F. Tacconi and A. Billio and E. Ascari and O. Prinoth and M. Rubertelli and G. Ongaro and F. Rodeghiero and C. Perotti and G. Busnach and G. Cambie and A. Canevari and M. Carotenuto and G. Leda and G. Bertrand",
year = "1994",
language = "English",
volume = "52",
pages = "222--226",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange

AU - Bobbio-Pallavicini, E.

AU - Porta, C.

AU - Centurioni, R.

AU - Gugliotta, L.

AU - Vianelli, N.

AU - Tacconi, F.

AU - Billio, A.

AU - Ascari, E.

AU - Prinoth, O.

AU - Rubertelli, M.

AU - Ongaro, G.

AU - Rodeghiero, F.

AU - Perotti, C.

AU - Busnach, G.

AU - Cambie, G.

AU - Canevari, A.

AU - Carotenuto, M.

AU - Leda, G.

AU - Bertrand, G.

PY - 1994

Y1 - 1994

N2 - Among all the patients treated by the Italian Cooperative Group for TTP, we retrospectively reviewed the results obtained using vincristine (VCR) in 8 TTP patients (4 men and 4 women, average age: 39.25 years, range: 23-48) who did not respond to combined apheretic and pharmacologic treatment. All patients, after failing to respond to treatment, were started on VCR at the dose of 2 mg, i.v., once a week. Despite this treatment, 4 patients (50%) died 1, 7, 12 and 25 days after the first VCR dose, respectively. The other 4 patients who received VCR achieved complete remission 24, 30, 40 and 50 days from the beginning of the treatment. Total doses of VCR ranged from 2 to 6 mg in the deceased group, and from 6 to 14 mg in the cured patients. In our experience, VCR is a promising agent to treat TPP patients resistant to conventional plasma-exchange and pharmacologic therapy.

AB - Among all the patients treated by the Italian Cooperative Group for TTP, we retrospectively reviewed the results obtained using vincristine (VCR) in 8 TTP patients (4 men and 4 women, average age: 39.25 years, range: 23-48) who did not respond to combined apheretic and pharmacologic treatment. All patients, after failing to respond to treatment, were started on VCR at the dose of 2 mg, i.v., once a week. Despite this treatment, 4 patients (50%) died 1, 7, 12 and 25 days after the first VCR dose, respectively. The other 4 patients who received VCR achieved complete remission 24, 30, 40 and 50 days from the beginning of the treatment. Total doses of VCR ranged from 2 to 6 mg in the deceased group, and from 6 to 14 mg in the cured patients. In our experience, VCR is a promising agent to treat TPP patients resistant to conventional plasma-exchange and pharmacologic therapy.

KW - plasma-exchange

KW - refractory disease

KW - TTP

KW - vincristine

UR - http://www.scopus.com/inward/record.url?scp=0028225739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028225739&partnerID=8YFLogxK

M3 - Article

C2 - 8005232

AN - SCOPUS:0028225739

VL - 52

SP - 222

EP - 226

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 4

ER -